//
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential
Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart Failure
Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block
Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients
Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation